229 related articles for article (PubMed ID: 34057651)
1. Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells.
Bernhardt SM; Dasari P; Glynn DJ; Townsend AR; Price TJ; Ingman WV
Breast Cancer Res Treat; 2021 Jun; 187(3):681-693. PubMed ID: 34057651
[TBL] [Abstract][Full Text] [Related]
2. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
3. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
6. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
8. The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype.
Need EF; Selth LA; Trotta AP; Leach DA; Giorgio L; O'Loughlin MA; Smith E; Gill PG; Ingman WV; Graham JD; Buchanan G
BMC Cancer; 2015 Oct; 15():791. PubMed ID: 26498662
[TBL] [Abstract][Full Text] [Related]
9. Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer.
Fowler AM; Salem K; DeGrave M; Ong IM; Rassman S; Powers GL; Kumar M; Michel CJ; Mahajan AM
Horm Cancer; 2020 Apr; 11(2):63-75. PubMed ID: 31942683
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression.
Dotzlaw H; Miller T; Karvelas J; Murphy LC
Cancer Res; 1990 Jul; 50(14):4204-8. PubMed ID: 2364377
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen impairs prepubertal mammary development and alters expression of estrogen receptor α (ESR1) and progesterone receptors (PGR).
Tucker HL; Parsons CL; Ellis S; Rhoads ML; Akers RM
Domest Anim Endocrinol; 2016 Jan; 54():95-105. PubMed ID: 26619291
[TBL] [Abstract][Full Text] [Related]
12. Anti-proliferative transcriptional effects of medroxyprogesterone acetate in estrogen receptor positive breast cancer cells are predominantly mediated by the progesterone receptor.
Moore NL; Hanson AR; Ebrahimie E; Hickey TE; Tilley WD
J Steroid Biochem Mol Biol; 2020 May; 199():105548. PubMed ID: 31805393
[TBL] [Abstract][Full Text] [Related]
13. Activity of taspine isolated from Radix et Rhizoma Leonticis against estrogen-receptor-positive breast cancer.
Zhan Y; Zhang Y; Chen Y; Wang N; Zheng L; He L
Fitoterapia; 2011 Sep; 82(6):896-902. PubMed ID: 21605638
[TBL] [Abstract][Full Text] [Related]
14. ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.
Hertz DL; Henry NL; Kidwell KM; Thomas D; Goddard A; Azzouz F; Speth K; Li L; Banerjee M; Thibert JN; Kleer CG; Stearns V; Hayes DF; Skaar TC; Rae JM
Physiol Genomics; 2016 Sep; 48(9):688-98. PubMed ID: 27542969
[TBL] [Abstract][Full Text] [Related]
15. Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
Bendrat K; Fritz P; Müller S; Brockmöller S; Debus A; Friedrichs K; Lindner C; Brinkmann F; Heidemann E; Niendorf A
Anticancer Res; 2016 Aug; 36(8):3855-63. PubMed ID: 27466487
[TBL] [Abstract][Full Text] [Related]
16. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Msx2 gene expression by steroid hormones in human nonmalignant and malignant breast cancer explants cultured in vitro.
Malewski T; Milewicz T; Krzysiek J; Gregoraszczuk EL; Augustowska K
Cancer Invest; 2005; 23(3):222-8. PubMed ID: 15945508
[TBL] [Abstract][Full Text] [Related]
18. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
[TBL] [Abstract][Full Text] [Related]
19. Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Tong D; Schneeberger C; Czerwenka K; Schmutzler RK; Speiser P; Kucera E; Concin N; Kubista E; Leodolter S; Zeillinger R
Clin Cancer Res; 1999 Jun; 5(6):1497-502. PubMed ID: 10389938
[TBL] [Abstract][Full Text] [Related]
20. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
